HemOnc Today


The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

Financial disclosure in oncology leaves ‘room for standardization’


Should there be more focus on the financial relationship itself rather than its disclosure?


NCCN’s off-label cancer treatment recommendations ‘constitute a problem’


Oxygen: A ‘Nobel’ gas

Derek Raghavan, MD, PhD

Advanced Practice

Treating the patient throughout the surgical process using evidence-based practice

Lisa Parks, MS, APRN-CNP, ANP-BC


Vincristine shortage underscores vulnerability of ‘fragile market’ for crucial treatments

CAR T-cell therapy has some patients crowdfunding to cover costs

AACR Cancer Progress Report: Past federal investments in NIH spurring breakthroughs in care

Study suggests NCCN off-label recommendations valid based on available evidence

Access to care among ‘critical priorities’ for American Cancer Society’s new chief medical, scientific officer

Biomarkers could help identify children with cancer at risk for cognitive impairments

Meeting News

Clinical trial participation studies show possible survival benefit, misconceptions of patient concerns

African Americans, Hispanics less likely than whites to use hospice for pancreatic cancer

Atezolizumab extends OS for PD-L1-selected patients with non-small cell lung cancer

Nivolumab extends OS in advanced esophageal squamous cell carcinoma

Immunotherapy-chemotherapy combination may reduce recurrence of triple-negative breast cancer

Addition of veliparib to platinum chemotherapy extends PFS in BRCA-mutated breast cancer

Atezolizumab extends PFS in metastatic urothelial cancer

Apalutamide improves OS in nonmetastatic, castration-resistant prostate cancer

Targeted therapy shows benefit in advanced cholangiocarcinoma

Triplet therapy improves outcomes in BRAF V600E-mutant metastatic colorectal cancer

Veliparib regimen extends PFS in newly diagnosed high-grade serous ovarian carcinoma

Addition of olaparib to maintenance bevacizumab significantly improves PFS in ovarian cancer

Addition of M6620 to gemcitabine prolongs PFS in platinum-resistant ovarian cancer

Nivolumab-ipilimumab combination confers durable OS, PFS benefit in metastatic melanoma

Speaker: Rationale exists to test CAR T-cell therapy in KRAS-mutated lung cancer

First-line durvalumab plus chemotherapy improves OS in extensive-stage small cell lung cancer

Video-assisted thoracic surgery linked to fewer complications in early lung cancer

Tumor mutational burden an ineffective biomarker for response to pembrolizumab plus chemotherapy

Survey reveals ‘suboptimal awareness’ of lung cancer molecular testing guidelines

IASLC: All physicians should screen patients with cancer for tobacco use

Drug costs, prior authorizations create barriers to timely cancer care

In the Journals

Gilteritinib new standard of care for relapsed, refractory FLT3-mutated acute myeloid leukemia

Ibrutinib plus venetoclax safely induces remission in relapsed, refractory chronic lymphocytic leukemia

Clinically indicated ibrutinib interruptions do not limit long-term benefit in CLL

Symptom burden a key component of disease control assessment in polycythemia vera

Daratumumab regimen reduces risk for progression, death in newly diagnosed multiple myeloma

OS rate for Hodgkin lymphoma remains high with PET response-adapted therapy

Treatment for Hodgkin lymphoma during pregnancy appears safe

Triplet therapy active in diffuse large B-cell lymphoma

CD19-specific CAR T-cell therapy feasible for aggressive non-Hodgkin lymphoma

Concizumab effective, safe for certain patients with hemophilia

Transfusion timing, volume do not affect mortality among African children with severe anemia

Greater cardiorespiratory fitness may reduce risk for venous thromboembolism

Birth defects linked to increased risk for childhood cancer

Foreign-born women less likely to have had a mammogram

Molecular analysis may aid in tailoring treatment for certain patients with colorectal cancer

Nivolumab with higher ipilimumab dose shows promising efficacy for bladder cancer

Nivolumab-bevacizumab combination safe, active in relapsed ovarian cancer

Adjuvant whole-brain radiotherapy ‘should not be recommended’ for certain patients with melanoma brain metastases

Aggressive radiotherapy dose de-escalation confers benefits in HPV-associated oropharyngeal squamous cell carcinoma

High-deductible health plans linked to delayed, forgone care among cancer survivors

FDA News

FDA grants priority review to zanubrutinib for relapsed/refractory mantle cell lymphoma

FDA grants fast track designation to navicixizumab for pretreated ovarian cancer

FDA grants orphan drug designation to Imfinzi for small cell lung cancer

FDA grants breakthrough therapy designation to Calquence for chronic lymphocytic leukemia

FDA approves Xarelto to prevent blood clots in acutely ill hospitalized patients

FDA grants priority review to Xtandi for metastatic hormone-sensitive prostate cancer

FDA approves Ruxience, biosimilar to Rituxan, for blood cancers, autoimmune conditions

FDA approves pexidartinib, first therapy for tenosynovial giant cell tumor

FDA awards $15 million to fund trials of treatments for rare diseases

In the Journals

Childhood leukemia survivors may be at higher risk for infections

Cancer researchers receive Lasker-DeBakey Clinical Medical Research Award

Society honors Helen F. Graham Cancer Center medical director

Cleveland Clinic appoints hematology/medical oncology department chair

The Leukemia & Lymphoma Society awards $13.8 million for research into pediatric blood cancers

The Wistar Institute researcher receives NIH New Innovator Award

Ohio State cancer center appoints hematology division director

Cancer Research Institute honors UCLA scientist for basic, tumor immunology discoveries

Researchers share Nobel Prize for discoveries that may improve treatment of cancer, anemia